PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update

Figures & data

Figure 1 Pegylated interferon: a ribbon protein with a polymer linked by a bridge between two multicolored cysteine residues.

Note: Reproduced with permission from Dr Mire Zloh.

Figure 2 Pharmacokinetics for PEG-IFN beta-1a. (A) Pharmacokinetic effects from the cytopathic effect assay in the single-dose study. (B) Pharmacokinetic profiles from the enzyme-linked immunosorbent assay in the multidose study.

Note: Reproduced with permission from SAGE Publications (Copyright © 2012, all rights reserved), from Hu X, Miller L, Richman S, et al. A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology. J Clin Pharmacol. 2012;52(6):798–808.²⁵
Abbreviations: SC, subcutaneous; IFN, interferon; IM, intramuscular; PEG-IFN, PEGylated interferon; PEG, polyethylene glycol; q2w, once every 2 weeks; q4w, once every 4 weeks.

HuXMillerLRichmanSA novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyJ Clin Pharmacol201252679880821680782

 PubMed Web of Science ®Google Scholar